Moderate neonatal jaundice is the most common clinical condition during newborn life. However, a combination of factors may result in acute hyperbilirubinemia, placing infants at risk of developing bilirubin encephalopathy and death by kernicterus. While most risk factors are known, the mechanisms acting to reduce susceptibility to bilirubin neurotoxicity remain unclear. The presence of modifier genes modulating the risk of developing bilirubin-induced brain damage is increasingly being recognised. The Abcb1 and Abcc1 members of the ABC family of transporters have been suggested to have an active role in exporting unconjugated bilirubin from the central nervous system into plasma. However, their role in reducing the risk of developing neurological damage and death during neonatal development is still unknown. To this end, we mated Abcb1a/b -/-and Abcc1 -/-strains with Ugt1 -/-mice, which develop severe neonatal hyperbilirubinemia.
Abstract
Moderate neonatal jaundice is the most common clinical condition during newborn life. However, a combination of factors may result in acute hyperbilirubinemia, placing infants at risk of developing bilirubin encephalopathy and death by kernicterus. While most risk factors are known, the mechanisms acting to reduce susceptibility to bilirubin neurotoxicity remain unclear. The presence of modifier genes modulating the risk of developing bilirubin-induced brain damage is increasingly being recognised. The Abcb1 and Abcc1 members of the ABC family of transporters have been suggested to have an active role in exporting unconjugated bilirubin from the central nervous system into plasma. However, their role in reducing the risk of developing neurological damage and death during neonatal development is still unknown. To this end, we mated Abcb1a/b -/-and Abcc1 -/-strains with Ugt1 -/-mice, which develop severe neonatal hyperbilirubinemia.
While about 60% of Ugt1 -/-mice survived after temporary phototherapy, all Abcb1a/b -/-/Ugt1 -/-mice died before postnatal day 21 , showing higher cerebellar levels of unconjugated bilirubin. Interestingly, Abcc1 role appeared to be less important.
In the cerebellum of Ugt1 -/-mice, hyperbilirubinemia induced the expression of Car and Pxr nuclear receptors, known regulators of genes involved in the genotoxic response. We demonstrated a critical role of Abcb1 in protecting the cerebellum from bilirubin toxicity during neonatal development, the most clinically relevant phase for human babies, providing further understanding of the mechanisms regulating bilirubin neurotoxicity in vivo. Pharmacological treatments aimed to increase Abcb1 and Abcc1 expression, could represent a therapeutic option to reduce the risk of bilirubin neurotoxicity.
Introduction
Hyperbilirubinemia is the most common clinical condition during neonatal life and is a continuing concern to paediatricians. It occurs in up to 60% of full-term and 80% of preterm newborns, with an estimated incidence of acute UCB encephalopathy (or kernicterus) in high-income countries of 0.4-2.7/100,000 live births, while it is considerably higher in underdeveloped and developing countries (1) . There is a large variability in the extent of neurological damage caused by similar levels of bilirubin in different newborns and there is no clear threshold value of bilirubin level that could with certainty predict the onset of bilirubin-induced neurological dysfunction (BIND) or kernicterus (2, 3) . Most children have no identified aetiology other than a combination of factors known to be associated with higher risk of bilirubin injury (4, 5) . The possibility to modulate the risk of developing neonatal hyperbilirubinemia by the presence of modifier genes is increasingly being recognised (6, 7) . These genes, as well as others affecting bilirubin metabolism, may interact in vivo with each other and/or with other risk factors resulting in different hyperbilirubinemic and developmental conditions leading to different neurological outcomes (4, 7) .
Drug transport in the central nervous system is highly regulated by the blood-brain and the blood-cerebrospinal fluid barriers (8) . Members of the super-family of ABC transporters, belonging to the ABCB [e.g., ABCB1/P-glycoprotein (P-gp)], ABCC (multidrug resistance-associated proteins, MRPs; e.g., ABCC1/ MRP1), and ABCG [e.g., ABCG2/breast cancer resistance protein (BCRP)] subfamilies, constitute the major transport systems restricting drug permeability across the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB), ultimately affecting drug elimination and distribution in the brain (9) .
It has been postulated that ABCB1 and ABCC1 constitute active bilirubin-clearance mechanisms exporting UCB back from the central nervous system (CNS) into the plasma, thereby limiting the accumulation of unbound bilirubin in the cerebrospinal fluid (CSF) and in the CNS (5, (10) (11) (12) (13) (14) . Both transporters protect the brain from different insults (15, 16) and their localization in the CNS is appropriate to pump UCB from CNS cells and CSF into the blood, respectively. ABCB1 is localised in the luminal side of the capillary endothelial cells of the blood-brain barrier (facing the blood) (17, 18) , while ABCC1 is present in the basolateral face of the choroid plexus epithelium of the bloodcerebrospinal fluid barrier (16, 19) .
The initial evidence of ABCB1 and ABCC1 in bilirubin transport was derived from experiments in tissue culture cells (12, (20) (21) (22) . Moreover, in vitro and in vivo experimental evidences support a role for both ABCB1 and ABCC1 in limiting intracellular concentration of UCB, modifying its regional distribution, decreasing its toxicity and protecting CNS cells against accumulation and toxicity of UCB (13, (23) (24) (25) . However, the in vivo experiments were performed using a single artificial dosing of bilirubin concentration, in adult Abcb1a -/-mice and in WT rats treated with compounds inhibiting Abcb1 activity, reaching bilirubin concentrations in plasma vastly higher than clinically relevant levels (13, 25) . Thus, it was not possible to determine the actual biological significance of these transporters to neutralize bilirubin neurotoxicity in physiological conditions and during postnatal development, the period of highest risk for permanent neurological damage by bilirubin (5) . Today, the availability of genetic mouse models of hyperbilirubinemia combined with knock-out (KO) strains of the transporters allows the study of the real role of Abcb1 and Abcc1 bilirubin transporters during postnatal neurological development in severe hyperbilirubinemia conditions, closely mimicking the human situation (26, 27) .
In the present work, we generated double and triple KO strains, by mating Ugt1 -/-mice (26, 27) with KO mouse strains of the Abcb1 and Abcc1 transporters (15, 28) to study the role of the Abcb1 and Abcc1 bilirubin transporters during neonatal development in hyperbilirubinemic conditions. We demonstrated the critical role of Abcb1 in protecting mutant mice from bilirubin toxicity, while the role of Abcc1 was less important. We have also shown that, in the cerebellum of Ugt1 -/-mice, hyperbilirubinemia increased the expression of the nuclear receptors Car and Pxr, known regulators of genes involved in the genotoxic response (29) . These important results provide further understanding of the mechanisms regulating bilirubin neurotoxicity in vivo.
Results

Hyperbilirubinemia triggers Abcb1 and Abcc1 gene expression in the brain
To assess the potential role of Abcb1 and Abcc1 in the modulation of bilirubin neurotoxicity, we applied an in vivo genetic approach by mating a hyperbilirubinemic mouse strain lacking Ugt1a1 glucuronosylation activity (26, 27) with mouse strains bearing targeted null mutations in the Abcb1a/b and Abcc1 genes (28, 30) , in order to generate double and triple mouse strains
). To note, the Abcb1 gene in mice is composed of two closely linked members, Abcb1a and Abcb1b (31), both are expressed in brain (32) , thus, we used a strain having the combined Abcb1a/Abcb1b double gene mutation (30) . Since Abcb1a and Abcb1b genes segregate together, from now on we will refer to this strain as the Abcb1 -/-mice.
All untreated Ugt1 -/-mutant mice in the FVB/NJ genetic background die before post-natal day 15 (P15), with 50% mortality at P11 (26) . The Abcb1 -/-and Abcc1 -/-strains, which were also in FVB/NJ genetic background, showed no mortality as previously reported (28, 30) . The Ugt1 -/-mouse model shows an important degeneration of cerebellar neurons with poor or null involvement of other brain regions (26, 27) . Thus, we divided the brain into two regions: forebrain and cerebellum. Next, we determined Abcb1a [as it is the one expressed both in forebrain and cerebellum (32) ] and Abcc1 expression levels by qRT-PCR at different time points in the cerebellum and forebrain of untreated wild type (WT) mice, from postnatal day 1 (P1) up to P18. We observed that the Abcb1 and Abcc1 transporters were expressed in both regions of the brain since P1 (Supplementary Material, Fig. S1A-D) . Western blot analysis of cerebellar samples at different time points showed a marked increase of Abcb1 protein levels at P15 and P18 (Supplementary Material, Fig. S1E ).
Then, to determine whether Abcb1 and Abcc1 gene expression are modulated by bilirubin, we performed a time-course analysis of their mRNA expression levels in the cerebellum of the untreated hyperbilirubinemic Ugt1 -/-mice by qRT-PCR and Western blot analysis (P5, P8 and P10). It is important to note that P10 corresponds to the latest and most severe phase of the hyperbilirubinemic condition, just one day before reaching 50% mortality (26) . We observed an increase in Abcb1 mRNA levels at both P5 and P8, reaching up to 3-times the levels of WT mice (Fig. 1A) , while mRNA levels at P10 were similar to those of WT cerebella. Abcc1 mRNA expression was also increased at P5 (about 2-times the levels of WT mice), although this difference was not statistically significant (2-way ANOVA, NS; Fig. 1A ).
Western blot analysis at P8 using Abcb1-and Abcc1-specific antibodies confirmed an increase in the expression levels of Abcb1 in the Ugt1 -/-samples (of about 2 times compared to WT) in response to increasing levels of bilirubin, while the levels of the Abcc1 transporter were similar to WT (Figs 1B and C). Since nuclear pregnane X receptor (Pxr) and constitutive androstane receptor (Car) were reported to modulate Abcb1 gene expression in response to xenobiotics and during changes in the levels of endogenous metabolites (33, 34) , we explored whether expression of these two nuclear receptors was modified by hyperbilirubinemia during the early neonatal phases. To this end, we performed a time course analysis of mRNA expression levels in WT and Ugt1 -/-cerebella. We did not observe any change in mRNA levels by qRT-PCR at any of the time points analysed (Fig. 1A) . Then, we determined the mRNA levels of other nuclear receptors that mediate transcription of ABC transporters in the brain, such as the aromatic hydrocarbon receptor (AhR), peroxisome proliferator-activated receptor alpha (Ppar-a) and Nuclear Receptor Subfamily 1 Group H Member 2 (Nr1h2) (8, 35, 36) by qRT-PCR. Similarly, no statistically significant differences were observed for any of these nuclear receptors analyzed (P10, Supplementary Material, Fig. S2 ).
The absence of the Abcb1 and Abcc1 transporters does not influence survival of Ugt1 -/-mice in a severe hyperbilirubinemic condition
To determine the role of Abcb1 and Abcc1 in the detoxification of bilirubin, we compared the survival of the Abcb1 -/-/Ugt1 -/-and
Abcc1
-/-/Ugt1 -/-double knockout (DKO) strains with that of the Ugt1 -/-strain during very severe hyperbilirubinemic conditions.
As mice received no treatment to reduce the severity of hyperbilirubinemia, the Ugt1 -/-strain did not survive after postnatal day 15, with 50% mortality at P11 [ Fig. 2A and (26)]. If the Abcb1 or the Abcc1 transporters were important for the disposal of bilirubin from the brain in these conditions, it would be expected that the DKO mice (Ugt1
) would have a further reduced lifespan. However, no differences in survival were observed among the three mutant strains (Ugt1
-/-and Abcc1 -/-/Ugt1 -/-), as shown in the KaplanMeier plot of Fig. 2A . These results showed that Abcb1 and Abcc1 transporters have a negligible role in modulating bilirubin accumulation in the brain and survival of mice in very severe hyperbilirubinemic conditions. Analysis of UCB plasma levels of all strains at different time points (P2, P5, P8 and P10) showed increased levels over time, reaching about 15 mg/dl at P10. In all strains having the Ugt1 -/-mutation we observed statistically significant differences in comparison with the WT littermates, but no differences were present among the mutant strains (Fig. 2B) . These results indicate that Abcb1 and Abcc1 transporters do not modify systemic bilirubin levels.
To determine whether the absence of Abcb1 and Abcc1 transporters could increase the susceptibility to bilirubin in other cell types, we prepared embryonic fibroblasts (MEF) from WT, Abcb1 -/-, Abcc1 -/-and Abcb1 
Abcb1 and Abcc1 transporters impact survival of Ugt1
-/-mice in a less severe hyperbilirubinemic condition
We considered that the potential modulatory role of the Abcb1 and Abcc1 transporters might be obscured by the extreme severity of hyperbilirubinemia in the absence of any other treatment. Therefore, we determined survival of the mutant strains in a less severe condition previously determined in our laboratory, by temporarily treating mice with phototherapy (PT) (26) . Again, if transporters had a role in bilirubin detoxification in these milder conditions, DKO and TKO mouse strains would have a lifespan shorter than that of Ugt1 -/-mice. Mice were treated with PT (12 h per day) for the first 10 days of life, a treatment that results in about 40-45% mortality (26) . After 10 days the PT treatment was discontinued and survival of mice was monitored (Fig. 3A) . In addition to the Abcb1
Abcc1
-/-/Ugt1 -/-strains, we also generated the triple KO strain 3A , white squares).
After removal of mice from the PT treatment, plasma bilirubin levels increased in all mutant genotypes, but no differences were observed among the genotypes after the discontinuation of the PT treatment (Fig. 3B ), similarly to that observed in younger untreated pups (Fig. 2B) .
As previously reported, 10 days of PT treatment resulted in increased survival of Animals were sacrificed at indicated time points and plasma levels of total bilirubin (TB) were determined. Values represent the mean 6 SD. The number of mice was !3 for all the genotypes and time points. Two-way ANOVA. Interaction time-genotype ***P < 0.001, genotype ***P < 0.001, time ***P < 0.001.
and white squares, respectively), with mice presenting seizures followed by death before P24. These data strongly support the importance of Abcb1 in the modulation of bilirubin neurotoxicity and, consequently, the susceptibility of the animals to damage by UCB. In addition, the Kaplan-Meier mortality curve of the triple KO strain Abcb1 -/-/Abcc1
-/-/Ugt1a1 -/-was similar to that of the double KO strain Abcb1
-/-/Ugt1 -/-suggesting no relevant interaction between the Abcb1 and Abcc1 transporters, confirming the key role of the Abcb1 transporter in these conditions. Next, we investigated whether the absence of Abcb1 may have an effect in the survival of mutant mice in a milder condition, by treating Ugt1 -/-KO and Abcb1 -/-/Ugt1 -/-DKO animals with PT up to postnatal day 15, a treatment previously shown to rescue all Ugt1 -/-KO animals (26) . Both groups of animals were rescued by the treatment (Supplementary Material, Fig. S5 ), suggesting the less relevant role of Abcb1 in the modulation of bilirubin neurotoxicity in these milder conditions.
Gene expression modulation of Pxr and Car nuclear receptors occurs in severe hyperbilirubinemia conditions
To get a deeper insight in the molecular mechanisms associated with Abcb1 and Abcc1 transporters in severe hyperbilirubinemic conditions, we determined their expression levels after removal, at P10, of Ugt1 -/-mutant mice and their WT littermates from the PT treatment, at post-natal days 13, 15 and 18. In the forebrain, the expression levels of Abcb1a and Abcc1 mRNA remained unresponsive to increased TB levels in Ugt1 Fig. S6 ). On the contrary, Abcb1a and Abcc1 mRNA expression levels increased significantly in the cerebellum of Ugt1 -/-mice after the sudden rise of plasma bilirubin levels (from two-fold at P13 to 3.5-fold at P18, Fig. 4A ). These results showed that cerebellar Abcb1 expression seems to be induced by hyperbilirubinemia. Similarly, there was a significant increase of Abcc1 levels in the cerebella at P15 (up to 3-fold, Fig. 4A ).
Comparison of Abcb1 and Abcc1 mRNA expression levels by qRT-PCR analysis in the forebrain and cerebella of WT and Ugt1 -/-mice showed that the expression of Abcb1 was much higher than Abcc1 at all time points analysed (P13, P15 and P18, Supplementary Material, Fig. S7 ). At each time point the data for Abcb1 and Abcc1 were normalised to a-tubulin in forebrain and TBP in the cerebellum, then normalization across genes was performed against WT Abcc1 expression. The highest difference observed between Abcb1 and Abcc1 mRNA levels was 20-fold in the cerebellum of Ugt1 -/-mice, at P18.
Unexpectedly, despite the significant differences in mRNA levels between WT and Ugt1 -/-cerebellar samples, Western blot experiments performed at P15 using cerebellar extracts of WT and Ugt1 -/-animals showed that Abcb1 and Abcc1 protein levels were similar between the two genotypes ( Fig. 4B and C) . Subsequently, we analysed whether the expression levels of Pxr and Car mRNAs were modified by bilirubin levels in this condition (P0-P10 PT) (Fig. 4A) . We observed that the mRNAs of both receptors were differentially expressed in the cerebella of Ugt1 -/-animals, in comparison to WT littermates. In fact, Pxr mRNA expression was upregulated at P18 (Fig. 4A) , while Car mRNA levels were significantly increased at P13 and P15, but this effect was lost at P18 (Fig. 4A) . On the contrary, in the forebrains we observed were no differences in the expression of both Pxr and Car mRNAs between WT and Ugt1 -/-samples at any of the time points analysed (Supplementary Material, Fig. S6 ). These results showed that, in the cerebellum, the mRNAs of Car and Pxr nuclear receptors are up regulated in response to hyperbilirubinemia.
Determination of bilirubin content in brain
Despite the same systemic UCB levels in both the Abcb1
and Ugt1 -/-mice, the survival between the two strains Grey area indicates the period of phototherapy treatment. (B) Animals were sacrificed at indicated time points and plasma levels of total bilirubin (TB) were determined. Values represent the mean 6 SD. The number of mice was !3 for all the genotypes and time points. Two-way ANOVA. Interaction time-genotype ***P < 0.001, genotype ***P < 0.001, time ***P < 0.001.
drastically differed. Thus, since the accumulation of UCB in tissues is the primary cause of neurotoxicity, we determined the bilirubin content in the forebrain and cerebellum of these strains.
As Ugt1 DKO animals is occurring. At P18, despite the constant value of plasma bilirubin (Fig. 3B) , there was an important increase in tissue bilirubin content both in cerebellum and forebrain, although no differences between the two genotypes were observed (Figs 5A and B) . The highest increase occurred in the cerebellum, where bilirubin levels rose from 5 nmol/g at P13 to about 16 nmol/g at P18, thereby tripling in quantity, while in the forebrain the amount of bilirubin doubled, from 5 to 10 nmol/g. These biochemical data suggest that the absence of Abcb1 contributed to the observed increase in tissue bilirubin content 
Functional and histological analysis of cerebellum in mild hyperbilirubinemic condition
As bilirubin content in the cerebellum of Abcb1 -/-/Ugt1 -/-mice was increased, we tested whether these animals presented motor coordination abnormalities in a rotarod. All of the animals were treated for 10 days with PT and tested in two consecutive days, P16 and P17, after which (at P18) brain samples were harvested for histological analysis. We observed that Abcb1 Then, we performed a gross histological analysis of this brain region at P18. Nissl staining of brain sections showed that cerebellar layers and fissures were normally developed in all P0-P10 PT-treated Abcb1 -/-/Ugt1 -/-DKO animals, despite the lack of the transporter and higher tissue bilirubin content at P15 (Fig. 6B) . Measurement of cerebellar layers' thickness at P18 showed that neither granular layer (GL) nor molecular layer (ML) were significantly different across the genotypes (Fig. 6C) . Western blot determination of Calbindin 1 protein levels, as a marker of Purkinje cells (PCs), showed no differences in Calbindin 1 content across the genotypes, suggesting no evident PC impairment (Fig. 6D) . Taken together, these data showed no obvious impairment in cerebellar morphology. However, the difference obtained by the rotarod test suggested that a more subtle damage was present at P18, not detected in the present analysis.
Discussion
The main event leading to bilirubin encephalopathy is the diffusion of the lipophilic unbound fraction of UCB across the bloodbrain barrier (BBB), which accumulates in different brain regions to toxic levels. So far, however, the mechanisms employed by the brain to reduce UCB toxicity have remained largely unknown. One of the proposed mechanisms to avoid/reduce the risk of bilirubin neurotoxicity is the disposition of UCB from the CNS into the circulation by active transport (14,37). (12, (20) (21) (22) 24, 38, 39) and in vivo (13, 25) support the hypothesis of a potential role of the ABC transporters ABCB1 and ABCC1 in modulating bilirubin neurotoxicity (14) . Others and we have shown that expression of these transporters in newborns is timely to support a role in bilirubin clearance from the brain (10,14,38,40,41). However, despite the fact that this hypothesis has been suggested almost two decades ago (13, 14, 37) , the direct proof of the function of ABC transporters during neonatal development and in physiological hyperbilirubinemia was still missing.
Studies performed in vitro
Here, we addressed this question by using a clinically relevant mouse model of neonatal hyperbilirubinemia with a targeted mutation in the Ugt1a gene, in combination with knock-out strains of these key ABC transporters, with life or death as readout. Mutant mice presented clinical conditions that could be compared with those of newborns with acute neonatal hyperbilirubinemia which, if not treated in a timely manner, may develop permanent neurological damage and kernicterus (5).
We showed a critical role of Abcb1 in protecting from bilirubin neurotoxicity. In effect, the lack of Abcb1 rendered Abcb1 -/-/Ugt1 -/-TKO animals followed that of the Abcb1 -/-/Ugt1 -/-DKO mice, showing no significant synergistic effect when the Abcc1 mutation was added to Abcb1 -/-genetic background. We also detected significantly higher levels of UCB in the cerebella of Abcb1 -/-/Ugt1 -/-animals, demonstrating biochemically that Abcb1 is an important modulator of UCB content in the cerebellum. Surprisingly, we observed no differences in bilirubin content in the cerebellum at P18, probably related to the important increase in total levels both in Ugt1 -/-and Abcb1 -/-/Ugt1 -/-mice (from 4 to 6 nmol/g at P15 to $16 nmol/g at P18), which may have resulted in the saturation of the Abcb1 capacity to export bilirubin out from the cerebellar parenchyma. Our data indicate that the raise in tissue bilirubin levels and enhanced susceptibility to bilirubin neurotoxicity could be related to the lack of Abcb1 in mutant brains, with a consequent reduction in their capacity to dispose UCB, although some other so far unidentified neuroprotective effect of Abcb1 may play a role as well. The developmental phase of the CNS is a key point that defines neuronal vulnerability to bilirubin. We have previously demonstrated that the most critical time-window for neuronal susceptibility is between P8 and P12 in this mouse model (26) . Interestingly, this period coincides with the increase in Abcb1 protein levels observed in the cerebellum and other brain regions of mice, rats and humans (42) (43) (44) . It is expectable that the combination of the CNS maturation together with the modulation of Abcb1 may have a critical role in the attenuation of vulnerability to bilirubin toxicity. The low levels of Abcb1 observed in the first days after birth suggests a minor role in this timewindow. In contrast, at later stages (P15), Abcc1 expression increased and its levels well correlated with the degree of protection observed in Ugt1 -/-mice, as compared to Abcb1
-/-/Ugt1 -/-animals. As previously proposed by our group (26), the mouse model presented here closely mirrors the effect of hyperbilirubinemia in pre-term and term infants. In fact, pre-term babies do not express high levels of Abcb1 and are more susceptible to brain damage, while term neonates have higher Abcb1 expression levels and are less prone to develop bilirubininduced brain damage. Despite Abcc1 was a promising candidate (38, 39) , its in vivo contribution was apparently minor in the protection from bilirubin toxicity during severe hyperbilirubinemia. The potential major role for ABCC1 was supported by previous experiments showing its higher affinity for bilirubin when compared to ABCB1 (20) and its apparent higher capacity to clear bilirubin from intracellular space at modest UCB levels (39) . Collectively, these data were interpreted as the involvement of ABCC1 at a low intracellular bilirubin concentration while ABCB1 was suggested to act as an exporting mechanism at higher bilirubin content. The reasons of this discrepancy are probably related to the following observations: first, Abcc1 mRNA is less expressed than Abcb1 mRNA in both forebrain and cerebellum of mice; second, MEF cells expressed much higher levels of Abcc1 than Abcb1 mRNAs; and, third, MEF expressed much higher levels of Abcc1 mRNA compared to the mouse cerebellum, while the opposite was observed for Abcb1 mRNAs. Another important consideration regards the experimental model studied as, in the present work, data were generated in vivo using engineered mouse models, a condition that cannot be fully reproduced by in vitro approaches based on primary culture of neuronal cells and immortalised cell lines.
Interestingly, no differences in survival of the different strains were detected when PT was not applied, probably due to the very severe hyperbilirubinemia condition. We speculate that, in this extreme situation, Abcb1 (and eventually Abcc1) capacity to dispose bilirubin out from the brain is overwhelmed, resulting in irreversible neurological damage and early death of all mice (before P15), as already shown by our group (26) . Finally, Abcb1 presence was not essential in less severe conditions such as 15 days of PT, when bilirubin levels were no longer toxic. In fact, Abcb1
-/-/Ugt1 -/-mice survived, similarly to what was observed in untreated Abcb1 -/-and Abcc1 -/-single KO strains (15, 28, 30) . The modulation of UCB by Abcb1 acquire importance in conditions that are potentially critical for triggering neurological damage and death, but not in very severe or very mild conditions, such as absence or continuous PT treatment, respectively. Our results provide experimental support to the hypothesis that the huge variability in the extent of neurological damages observed at similar levels of bilirubin in human newborns could be associated with differences in ABCB1 and ABCC1 expression levels or activity, resulting from polymorphic variants of these genes. Polymorphisms in the ABCB1 gene are present in different ethnic groups with diverse frequencies, which were associated with alterations in drug disposition and drug response of a number of compounds (45) . Numerous studies have shown the influence of many of them in mRNA stability and protein levels (46, 47) , although in some cases with conflicting results. Unfortunately, no information is available regarding the effects of these variants on bilirubin transport. Likewise, a number of polymorphisms in the ABCC1 gene have been identified (11, 48) and there is accumulating evidence that several SNPs in the ABCC1 gene may contribute on drug response or disease susceptibility. The study of SNPs in ABCB1 and ABCC1 genes from patients with low levels of neonatal hyperbilirubinemia but presenting neurological damage (low bilirubin kernicterus) (49, 50) will further elucidate the role of these transporters in neurotoxicity, particularly in preterm neonates which are more susceptible to BIND and suffer adverse effects at lower TB levels with worse long-term outcomes.
During exposure to xenobiotics and endogenous toxic substances, CAR and PXR nuclear receptors are considered the first line of defense against a number of different compounds (51) , by modulating the transcriptional activity of multiple ABC transporters (52) and members of the UGT families (53, 54) , including ABCB1, ABCC1 and UGT1A1 (33, 34, 55, 56) . These receptors are members of the nuclear-receptor family of ligandactivated transcription factors, which get activated upon binding to a variety of xenobiotics with diverse chemical structures and, as in the case of CAR, translocate into the nucleus (57) . Chemical activation of both of CAR and PXR receptors in the brain resulted in higher Abcb1a expression levels (32, 33) . The involvement of bilirubin in the activation of PXR and CAR was shown using KO mice with artificially increased bilirubin levels (58, 59 ). In addition, Fujiwara et al. showed decreased mRNA expression of Abcb1 in brains of hUGT1/Car -/-mice (40). Our gene expression data are consistent with previous results showing activation effects of bilirubin (58, 59 ). In our model, we observed the upregulation of the mRNA levels of Abcb1 and Abcc1 transporters upon the acute bilirubin rise consequent to the interruption of the PT treatment, supporting their role in protection from genotoxic insults (5). However, the increase in Abcb1 and Abcc1 mRNAs was not accompanied by an augment of the transporters at the protein level, suggesting the presence of other mechanisms mediating translational repression, decreasing their half-life, or to an increase of unfolded proteins consequent to bilirubin-mediated ER stress. The activation of the unfolded protein response (UPR) may occur under stress conditions, resulting in the clearance of unfolded proteins throughout the endoplasmic reticulumassociated protein degradation pathway (ERAD) (60) . In support of this possibility, we observed an important increase in UPR and ER stress in the cerebellum of Ugt1 -/-mutant animals at this developmental stage (Vodret et al, unpublished) . This hypothesis, however, needs further testing since, at least in some stress-specific conditions, Abcb1 stability is increased (61) . One of the main mechanisms leading to translational repression is carried out by miRNAs, (62) . Interestingly, some miRNAs downregulating ABCB1 expression are also expressed at high levels in the brain (63, 64) but no information of their potential modulation by bilirubin is available.
The increase in mRNA and protein of Abcb1 during the initial phases of the disease, in very severe conditions (i.e., without PT treatment) could be the result of Car activation by bilirubin, without evident changes in the mRNA levels. However, we cannot rule out the involvement of other nuclear receptors, such as AhR or Nrf2 (which is activated at P5; Vodret et al, unpublished), which might mediate the up-regulation of Abcb1 levels during the first days after birth. On the contrary, in the animals temporarily treated with PT, it may be speculated that Car participates in the earlier response to bilirubin, while Pxr plays an important role during all phases of the response.
In summary, the results presented in this work are important for two reasons: (1) our genetically-induced hyperbilirubinemic mouse model reproduces the main features of severe neonatal jaundice (26, 27) ; and (2) the role of Abcb1 and Abcc1 were assessed during neonatal development, revealing a key role of Abcb1 in the survival of pups, while Abcc1 has a minor role, in a period clinically relevant for human babies (65) .
Another important conclusion is that neither Abcb1 nor Abcc1 absence affected systemic levels of bilirubin, as plasma bilirubin values were similar in both Ugt1 -/-KO and DKO mouse strains, ruling out that the observed differences in survival were related to changes in plasma bilirubin levels. The study of the mechanisms modulating bilirubin neurotoxicity is of crucial importance to understand the events leading to bilirubin-induced neurological damage (BIND) and kernicterus, and, eventually, to develop therapies aiming to prevent or revert this damage. Since differences in the genetic background and the presence of modifier genes could be related to the diverse susceptibility of human newborns, we believe that these results may also be relevant for the clinical medicine. We propose that pharmacological treatments aimed to increase the activity of Abcb1 and Abcc1, could represent a therapeutic option to reduce the risk of bilirubin neurotoxicity. On the contrary, drugs that inhibit Abcb1 activity including various antimicrobial agents, should be avoided in the presence of neonatal hyperbilirubinemia.
Materials and Methods
Animals
Mice were housed and handled according to institutional guidelines, and experimental procedures approved by the ICGEB board, with full respect to the EU Directive 2010/63/EU for animal experimentation. Ugt1 -/-mice in the FVB/NJ background have been generated previously (26) . Animals used in this study were at least 99.8% FVB/NJ genetic background, obtained after more than ten backcrosses with wild type FVB/NJ mice. WT littermates were used as control. Abcb1a/b -/-and Abcc1 -/-mouse strains bearing targeted null mutations in the Abcb1a/b and Abcc1 genes were generated previously by Prof. P. Borst laboratory and were originally in the FVB/c129 genetic background (28, 30) and then transferred to FVB/NJ by successive backcrosses to WT mice. The double and triple KO (Abcb1/Ugt1, Abcc1/Ugt1 and Abcb1/Abcc1/Ugt1) were generated by mating the Abcb1 and Abcc1 strains with the Ugt1 mice, which were also in the FVB/NJ genetic background (26) . Mice were kept in a temperature-controlled environment with 12/12 h light/dark cycle. They received a standard chow diet and water ad libitum.
Phototherapy treatment
Phototherapy treatment was performed as previously described (26) . Animals of the P0-P10PT control group were exposed to blue fluorescent light (20 lW/cm 2 /nm, Philips TL 20W/52 lamps;
Philips, Amsterdam, The Netherlands) for 12 h/day since birth up to postnatal day 10, and then maintained under normal light conditions.
Bilirubin determination in plasma
Blood from mice was collected as previously described (26) . Total plasma bilirubin levels were determined with the Direct and Total Bilirubin Reagent Kit (BQ Kits, Inc., San Diego, CA, USA) as previously described (26) .
Preparation of total RNA from the mouse cerebellum and real time PCR analysis
Total RNA from mouse brain regions was prepared using EuroGOLD Trifast (Euroclone), according to manufacturer's instructions. One mg of total RNA was reverse-transcribed using M-MLV (Invitrogen) and oligodT primers according to manufacturer's instructions. Total cDNA (1 ml) was used to perform qPCR using the specific primers listed in Supplementary Material, Table S1 . qPCR was performed using the iQ TM SYBR V R Green Supermix (Bio-Rad) and a C1000 Thermal Cycler CFX96 Real Time System (Bio-Rad). Expression of the gene of interest was normalised to the housekeeping gene as described below. Data were analysed using the DDCt method. The efficiency of the primers was checked by performing a qPCR with serial dilution of the target sequence (repeated 2 times) to determine the linear regression for efficiency and r 2 (r 2 ! 0.98) for these experimental data. Primers with inconsistent replicates and efficiency lower than 95% and were discarded. Due to variations in gene expression during the neonatal period, different housekeeping genes (glyceraldehyde 3-phosphate dehydrogenase, gapdh; hypoxanthine phosphoribosyltransferase 1, hprt1; a-tubulin, tuba1; TATA box binding protein, Tbp; cyclophilin, CypA; and b-actin, actb) were tested as potential genes for normalization of gene expression. Expression levels were normalised to the levels of a-tubulin mRNA in forebrain and TATA box binding protein (TBP) or Gapdh mRNA in the cerebellum, as those two housekeeping genes showed the most stable expression pattern throughout the period of interest.
Preparation of total protein extracts from the mouse brain and western blot analysis Cerebella and forebrains (brain minus the cerebellum) were dissected, homogenised in lysis solution buffer (150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris HCl pH 8, 2x protease inhibitors) and analysed by Western blot as described previously (26) . Primary antibodies used were as follows: anti-Abcb1 1:1000 (Cell Signaling, #13978), anti-Mrp1/Abcc1 1:500 (Enzo Life Sciences, MRPr1), anti-calbindin 1:2000 (Synaptic Systems, Goettingen, Germany), anti-b-tubulin mAb E7 1:1000 (Developmental Studies Hybridoma Bank, Iowa City, IA) and anti-Actin (1:1000, Sigma). Anti-Abcb1 and anti-Abcc1 specificity was tested using protein extracts derived from WT and KO animals (Supplementary Material, Fig. S4 ).
Tissue bilirubin analysis
Tissues for bilirubin content determination were collected and analysed as previously described (66) .
Rotarod analysis
At postnatal day 16 (P16), the coordination and balance ability of KO and WT mice were tested on a rotating cylinder with an accelerating apparatus, as previously described (27) . Briefly, animals were exposed to 3 trials at constant speed (slow, moderate and high: 2.8, 5.5, and 8.0 rpm, respectively) before the test. After these training sessions, mice were placed on the rotating rod with a linear increase in rotation speed from 2.5 to 48 rpm over a 5-min period. Mice that fell within 15 s of starting the trial were given a second chance. Mice were subjected to three trials of accelerating rotarod test for 2 consecutive days (at P16 and at P17), and the latency to fall was recorded, and the mean of each day calculated. The graph shows the mean value of the two days. Animals showing evident distress, seizures or moribund were not subjected to the test.
Brain histology
Nissl staining analysis of brain samples was performed as previously described (26, 27) . The study was performed in a doubleblind fashion: the genotype of the animals and the treatment were unknown to the surgeon, while a different investigator analysed the data. Measurements were averaged for each animal. /Abcc1 -/-animals as described previously (67) . Cells were cultured under standard conditions (5% CO 2 and 95% O 2 ), in Dulbecco's modified Eagle's high glucose medium (DMEM/high, Euro-lone No. EC M0106L) supplemented with 10% (v/v) fetal bovine serum, 2 mM l-glutamine, and 1% (v/v) penicillinstreptomycin (100 000 units/l penicillin and 100 mg/l streptomycin) at 37 C.
MEF preparation
Bilirubin treatment and cell viability test
Cells were used after 2 or 4 passages and were kept in culture for a week before being utilised. The day before the experiment MEF cells were plated in 24 multi-well plates (Corning Incorporated Costar V R 3526) at a density of 12 500 cells/cm 2 and 50 000 cells/cm 2 . The growth medium was discarded, the cells were washed with PBS at 37 C and then incubated with different concentrations of UCB. UCB (Sigma Chemical Co, St. Louis MO) was purified as described (68) . UCB required to reach the desired Bf (10-70 and 140 nM) was dissolved in 0.1%, 0.4% or 0.6% v/v of DMSO (10-70 and 140 nM, respectively) and diluted in complete medium with 15% FCS. Bf was measured as previously described (69) .
Once MEF cells achieved a 70-80% confluence the growing medium was discarded, cells were rinsed with PBS and exposed to medium containing 0.6% DMSO or UCB for 1 and 4 h. After the incubation period, medium-containing UCB was removed, cells were washed three times with PBS and then incubated with MTT 0.5 mg/mL for 2 h as previously described (70) . Then, the medium was discarded and MTT crystals were dissolved in DMSO. The absorbance values at 570 nm were determined in a LD 400C Luminescence Detector, Beckman Coulter, Milan, Italy. Results were expressed as percentage of MTT reduction respect to WT cells exposed to DMSO control.
Statistics
The Prism package (GraphPad Software, La Jolla, CA) was used to analyze the data. Results are expressed as mean 6 s.d. Values of P < 0.05 were considered statistically significant. Depending on the experimental design, Student's t-test or one-way or twoway ANOVA, with Bonferroni's post-hoc comparison tests were used, as indicated in the legends to the figures and text. Correlation analyses were done using the Pearson coefficient to assess the linearity between two variables and calculate twotailed P value (95% of confidence interval).
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